Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban Post-WATCHMAN LAA Closure
NCT03088072Phase 4Unknown
- Sponsor
- Scripps Health
- Start
- Mar 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of edoxaban in Atrial fibrillation (AFib), sponsored by Scripps Health. Primary endpoint: Death, stroke, systemic embolism or GUSTO outcomes at 6 weeks. Status: unknown.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03088072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03088072.